TY  - JOUR

T1  - Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model

JO  - Health Technology Assessment

UR  - http://eprints.whiterose.ac.uk/100350/

PY  - 2016/05/01

AU  - Archer R

AU  - Tappenden P

AU  - Ren S

AU  - Martyn-St James M

AU  - Harvey R

AU  - Basarir H

AU  - Stevens J

AU  - Carroll C

AU  - Cantrell A

AU  - Lobo A

AU  - Hoque S

ED  - 

DO  - DOI: 10.3310/hta20390

VL  - 20

IS  - 39

SP  - 1

EP  - 326

Y2  - 2024/12/22

ER  -